title: Hyperbaric oxygen as an adjunct in zygomycosis: randomized controlled trial in a murine model.
abstract: Zygomycosis was induced by injecting CD-1 mice with 5 mg of intraperitoneal deferoxamine and then 10(6) CFU of intravenous and intrasinus Rhizopus arrhizus. The addition of hyperbaric oxygen (2.0 atm absolute twice daily) to amphotericin B did not improve survival over that achieved with amphotericin B and placebo air treatments.
authors.affiliation: Section of Emergency Medicine and Hyperbaric Medicine, Department of Medicine, Louisiana State University, New Orleans, Louisiana 70112, USA. dbarratt@bellsouth.net
authors.forename: D M
authors.initials: DM
authors.lastname: Barratt
authors.forename: K
authors.initials: K
authors.lastname: Van Meter
authors.forename: P
authors.initials: P
authors.lastname: Asmar
authors.forename: T
authors.initials: T
authors.lastname: Nolan
authors.forename: C
authors.initials: C
authors.lastname: Trahan
authors.forename: L
authors.initials: L
authors.lastname: Garcia-Covarrubias
authors.forename: S E
authors.initials: SE
authors.lastname: Metzinger
mesh_terms: D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003676:Deferoxamine / Q000494:pharmacology; D005260:Female; D006931:Hyperbaric Oxygenation; D051379:Mice; D009091:Mucormycosis / Q000188:drug therapy / Q000628:therapy*; D012233:Rhizopus; D016019:Survival Analysis
chemical_list: D000935:Antifungal Agents; D000666:Amphotericin B; D003676:Deferoxamine